Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread
 of cancer through blood vessels to other organs (metastasis). The formation of new blood
 vessels is known as angiogenesis, which is controlled by a growth factor (like a hormone)
 called Vascular Endothelial Growth Factor (VEGF). Many drugs have been developed that block
 VEGF and, in most tumour types, including ovarian cancer, the addition of VEGF inhibitors
 (VEGFi) to conventional anti-cancer therapy postpones recurrence of the disease. In ovarian
 cancer, VEGFi improve the overall outcome from the cancer in patients who have advanced stage
 and high-risk disease. VEGFi are now widely used in cancer medicine, yet until now there have
 not been any biomarkers (tests) that could be used to tell patients and their doctors whether
 the drugs were working or not. This is important, as VEGFi have side effects that are
 unpleasant for the patient. Additionally, VEGFi treatments are expensive.

 The VALTIVE team has discovered the first biomarker that informs doctors whether a VEGFi is
 blocking a tumour's blood supply. The test involves measuring a protein in the blood called
 Tie2, which can be measured from routine blood tests that patients have when going to the
 hospital. If the test shows that the amount of Tie2 decreases in the blood, it means that
 tumour blood vessels are blocked by VEGFi; if, on the contrary, the level increases, the
 blood vessels have escaped the control of VEGFi.

 The investigators have shown that the Tie2 test works in their initial studies in ovarian and
 bowel cancer. In these studies, the Tie2 blood test was based in the research laboratories.
 The investigators now wish to establish the test in the Christie Hospital NHS Biochemistry
 laboratory in Manchester so that it can be used in clinical practice rather than just as a
 research tool. The investigators wish to measure the relationship between loss of control of
 VEGF inhibitors as measured by TIE 2 and other standard ways of measuring loss of control of
 the tumour like increases on CT scans. There are several reasons why this test is needed for
 patients with ovarian cancer:

 -  VEGFi are effective during a patient's first or subsequent treatments for advanced
 ovarian cancer, but it is not clear which individuals are benefitting from treatment
 whilst they are on treatment.

 -  Patients who have already had one course of VEGFi can be re-treated successfully.

 -  Patients can avoid needless side effects, if there is a way of demonstrating that the
 treatment is of no benefit to them.

 -  This test will help doctors choose the best drug to control ovarian cancer and how long
 to continue treatment. This is very important, since other maintenance therapies are now
 available and the optimal duration of VEGFi therapy is well known.

 -  Around the world many teams are developing new combination treatments including VEGFi.
 If these new combinations prove effective, it would be possible to use them as
 efficiently as possible, as they will be very expensive and may therefore be less
 accessible to patients.

 These issues highlight the critical need to establish a test in the NHS that tells patients
 and their doctors when VEGFi are working and when they stop working.

 In VALTIVE1 study, blood samples will be taken from patients who are receiving a VEGFi called
 bevacizumab for ovarian cancer. Patients' management will not change during their
 participation to the trial. The analysis of the blood sample will support the hypothesis that
 patients whose Tie2 level decreases in response to bevacizumab will have ovarian cancer that
 is controlled for much longer than those where the Tie2 level does not decrease. These
 results will be used to design a second trial where the investigators will prove conclusively
 the value of the Tie2 test.

 The purpose of VALTIVE1 is to optimise sample acquisition time points and analytical
 algorithms to support the design of VALTIVE2, a randomised discontinuation trial. In
 VALTIVE2, Tie2-defined, vascular non-responding patients will be randomly allocated to stop
 bevacizumab after 9 weeks, by when a response can be detected, or to continue bevacizumab for
 the conventional year of treatment.

 Both VALTIVE 1 and VALTIVE2 will test the theory that there is no advantage in continuing
 bevacizumab in a patient whose Tie2 level does not reduce in response to VEGFi.
VALTIVE1 is a multi-centre, single arm, non-interventional biomarker study, which will enrol
 176 participants who are 16 years or older and who have FIGO stage IIIc/ IV ovarian cancer on
 treatment with first-line platinum-based chemotherapy and bevacizumab. Potential participants
 will be identified at their treating hospital.

 The definition of vascular response is either (i) stable or reduced concentrations of Tie2
 after 6 weeks of treatment or (ii) a confirmed reduction in plasma Tie2 of >10% within 9
 weeks of starting treatment.

 Patients enrolled into the VALTIVE 1 study will provide blood samples twice before treatment
 with bevacizumab and then at the end Cycles 1, 2, and 3, at the end of cytotoxic
 chemotherapy, at 3 months, 6 months, 9 months, at the end of treatment, and at disease
 progression. The early samples will be used to refine the definition and number of required
 samples needed to define a Tie2-vascular response. Samples collected at 3 months, 6 months, 9
 months, at the end of treatment, and at disease progression will be used to investigate the
 relationship between Tie2-defined vascular progression and RECIST1.1- or clinically-defined
 Progression Disease (PD).

 While the patients receive single agent maintenance bevacizumab, patients will undergo
 RECIST1.1 scanning at 3 months, 6 months, 9 months, end of treatment and at disease
 progression, if not before. These scans will also be reported to RECIST 1.1.

 Progressive disease will be defined by the date of radiological or clinically identified
 progressive disease or death.
Inclusion Criteria:

 In order to be eligible for participation in this trial, the patient must:

 1. Be willing and able to provide written informed consent for the trial

 2. Age 16 years or over on day of signing informed consent

 3. Histologically proven Ovarian Cancer (OC) FIGO stage III with residual disease of more
 than 1cm; or stage IV; or stage III at presentation treated with neoadjuvant
 chemotherapy; or stage III with contraindication to debulking surgery chemotherapy

 4. Planned to receive treatment with bevacizumab or biosimilar bevacizumab

 5. Be scheduled to receive at least 2 successive doses of bevacizumab with 6 or more
 weeks of follow up blood samples after the first dose of bevacizumab if given
 pre-operatively; or to start bevacizumab post-operatively

 6. Be eligible for receiving treatment with first line platinum-based chemotherapy

 7. Be willing to provide blood samples and comply with trial-specific procedures

 Exclusion Criteria:

 The patient must be excluded from participating in the trial if the patient:

 1. Is unsuitable for treatment with VEGF inhibitors

 2. Is unable or unwilling to comply with study procedures

 3. Is participating in a clinical study with an investigational product other than
 carboplatin, paclitaxel and bevacizumab

 4. Is judged by the investigator to be unlikely to comply with study procedures

 5. Is pregnant or could become pregnant and is not using adequate contraception

 6. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

 7. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g. HCV RNA is
 detected). Testing only required if patient has a history of either of these